Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline and is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our focus on the patient is supported by clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development.
Adverum Biotechnologies NASDAQ: ADVM
$3.1510/21/164:00 p.m. ET
Data provided by Nasdaq.
Minimum 15 minutes delayed.
|There are currently no events scheduled.|